Clinical Outcomes in Patients With Acute Decompensated Heart Failure Randomly Assigned to Sacubitril/Valsartan or Enalapril in the PIONEER-HF Trial

Circulation. 2019 May 7;139(19):2285-2288. doi: 10.1161/CIRCULATIONAHA.118.039331.

David A Morrow^{1

2}, Eric J Velazquez³, Adam D DeVore⁴, Akshay S Desai², Carol I Duffy⁵, Andrew P Ambrosy^{6

7}, Yared Gurmu¹, Kevin McCague⁵, Ricardo Rocha⁵, Eugene Braunwald^{1

2}

¹ TIMI Study Group (D.A.M., Y.G., E.B.), Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.
² Cardiovascular Division (D.A.M., A.S.D., E.B.), Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.
³ Department of Internal Medicine, Yale University School of Medicine, New Haven, CT (E.J.V.).
⁴ Duke Clinical Research Institute, Duke University, Durham, NC (A.D.D.).
⁵ Novartis Pharmaceuticals Corporation, East Hanover, NJ (C.I.D., K.M., R.R.).
⁶ Department of Cardiology, Kaiser Permanente San Francisco Medical Center, San Francisco, CA (A.P.A.).
⁷ Section on Cardiovascular and Metabolic Conditions, Division of Research, Kaiser Permanente Northern California, Oakland (A.P.A.).

No abstract available

Keywords: enalapril; heart failure; hospitalization; valsartan.

Publication types